Last reviewed · How we verify
CD19 or CD19-BCMA CAR-T — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CD19 or CD19-BCMA CAR-T (CD19 or CD19-BCMA CAR-T) — Nanjing Bioheng Biotech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD19 or CD19-BCMA CAR-T TARGET | CD19 or CD19-BCMA CAR-T | Nanjing Bioheng Biotech Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD19 or CD19-BCMA CAR-T CI watch — RSS
- CD19 or CD19-BCMA CAR-T CI watch — Atom
- CD19 or CD19-BCMA CAR-T CI watch — JSON
- CD19 or CD19-BCMA CAR-T alone — RSS
Cite this brief
Drug Landscape (2026). CD19 or CD19-BCMA CAR-T — Competitive Intelligence Brief. https://druglandscape.com/ci/cd19-or-cd19-bcma-car-t. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab